Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Chad J. Warren"'
Autor:
Barbara A. Schweitzer, Atli Thorarensen, Michael S. Davies, Steve R. Turner, Matthew James Pelc, James R. Kiefer, Brenda L. Case, Christie L. Funckes-Shippy, Jacqueline E. Day, Fengmei Hua, Dice Tom, William M. Abraham, Bradley E. Neal, John I. Trujillo, Joseph B. Moon, Blake Tanisha Danielle Rowe, Wei Huang, Craig D. Wegner, Dean Welsch, Chris P. Carron, Anup Zutshi, Bruce C. Hamper, Chad J. Warren, Rhonda S. Woerndle, Christine M. Kornmeier, Vickie M. Dilworth, Melanie L. Williams, Martin E. Dowty, Olson Kirk Lang, Melissa R. Radabaugh, Becky L. Hood, Jerry Z. Yang, Douglas C. Rohrer, Gina M. Jerome, Christine P. Bono
Publikováno v:
ACS Medicinal Chemistry Letters. 1:59-63
Hematopoietic prostaglandin D synthase (HPGDS) is primarly expressed in mast cells, antigen-presenting cells, and Th-2 cells. HPGDS converts PGH2 into PGD2, a mediator thought to play a pivotal role in airway allergy and inflammatory processes. In th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e6559b7ee90a239bc2255e65f4dd700
https://doi.org/10.1021/ml900025z
https://doi.org/10.1021/ml900025z
Autor:
Steven L. Roberds, Steve P. Wene, Mark E. Smith, Chad J. Warren, Shuxia Zhou, Denise K. Pretzer, Jan L. Wahlstrom, Jon G. Selbo, Po-Chang Chiang, Sarbani Ghosh, L. Lena Zhang, Lesley A. Albin
Publikováno v:
Journal of Experimental Nanoscience. 2:239-250
Aqueous insolubility is recognized throughout the pharmaceutical industry as a major hurdle for pre-clinical and clinical drug delivery. Pre-clinical, early efficacy, and proof of concept studies oftentimes rely on model compounds that have less than
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f38ef66e1371ae21d0841d7a053646fa
https://doi.org/10.1080/17458080601134540
https://doi.org/10.1080/17458080601134540
Autor:
Sarbani Ghosh, Mark E. Smith, Jan L. Wahlstrom, Lesley A. Albin, Steven L. Roberds, Steve P. Wene, Chad J. Warren, Po-Chang Chiang
Publikováno v:
Nanoscale Research Letters
Nanoscale Research Letters, Vol 2, Iss 6, Pp 291-296 (2007)
Nanoscale Research Letters, Vol 2, Iss 6, Pp 291-296 (2007)
Time and resource constraints necessitate increasingly early decisions to advance or halt pre-clinical drug discovery programs. Early discovery or “tool” compounds may be potent inhibitors of new targets, but all too often they exhibit poor pharm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18154d324f6be5bc26c9e6e80c994563
http://europepmc.org/articles/PMC3246351
http://europepmc.org/articles/PMC3246351
Publikováno v:
Drug Metabolism and Disposition. 34:1966-1975
Drug-drug interactions may cause serious adverse events in the clinical setting, and the cytochromes P450 are the enzyme system most often implicated in these interactions. Cytochrome P450 2C is the second most abundant subfamily of cytochrome P450 e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9377a4104964643b7a46621fdd150af
https://doi.org/10.1124/dmd.106.010926
https://doi.org/10.1124/dmd.106.010926
When choosing a recombinant cytochrome P450 (P450) enzyme system for in vitro studies, it is critical to understand the strengths, limitations, and applicability of the enzyme system to the study design. Although literature kinetic data may be availa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4aeafa1a6c4d30cfe2a3ed206588088e
https://europepmc.org/articles/PMC2377028/
https://europepmc.org/articles/PMC2377028/
